Sign up to save your podcasts
Or
Share Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
129 Listeners
Global News Podcast
7,902 Listeners
Neurology® Podcast
288 Listeners
NEJM This Week
325 Listeners
Practical Neurology Podcast
44 Listeners
JAMA Clinical Reviews
493 Listeners
JAMA Neurology Author Interviews
14 Listeners
Annals On Call Podcast
185 Listeners
The Clinical Problem Solvers
515 Listeners
Neurology Minute
131 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
366 Listeners
The Lancet Neurology in conversation with
5 Listeners
Continuum Audio
78 Listeners